Hematology-Oncology Research Specialists

Hematological malignancies continue to demand more answers and there's a deep urgency for more effective treatments options. For over 15 years, our Hemato-Oncology research has contributed to some of the most impactful trials of this field. Today, we’ve evolved as an agile partner, leveraging advanced AI tools and patient registries to drive successful Phase I to III trials and support the entire lifecycle process.

gloved hand holds a blood sample tube, with a microscope in the background, representing specialized hematology-oncology research.

In-depth therapeutic expertise reducing
growing trial complexity

An icon of a person next to a shield with a cell pattern.

Experts in the field of Multiple Myeloma

Supported some of the most some of the most promising novel and emerging therapies.

An icon of a group of people inside a circular arrow.

Supporting the Entire Lifecycle Process

From Pre-Clinical Trials to Late Phase Trials.

An icon of a robot head with circuit lines and a check mark.

Artificial Intelligence Enabled

Access to AI tools and patient registries to target recruitment sites, and minimize enrollment timelines.

0
+

Trials

0
+

Patients

0
+

Global Sites

0

Countries

Rooted in years of therapeutic
insight and leadership

Every breakthrough in hematologic cancer care begins with a clear focus: the patient. We bring deep therapeutic insight and hands-on experience across a wide spectrum: from frontline and maintenance therapies to MRD-based strategies and intricate combination regimens. Our scientists have a rich experience in translating growing trial complexity into smart-adaptive designs, all guided by the goal of delivering better outcomes, faster. Whether it’s through adaptive protocols or decentralized models, we’ve helped sponsors accelerate the development of precision therapies for both broad and high-risk populations.

An icon set showing three types of blood cancers: an icon for Multiple Myeloma, an icon for Lymphoma (a torso with highlighted lymph nodes), and an icon for Leukemia (blood cells with an exclamation mark).

Creating trusted, long lasting relationships with KOLs and NFPs

Correct Icon

Collaborating with renowned KOLs in designing and monitoring Phase I to registrational Phase III clinical trials.

Correct Icon

10+ years of collaborative work with Europe's major NFPs and KOLs

Three scientists in a modern lab analyzing medical images of a brain on a large, interactive digital screen, symbolizing advanced research.
A pie chart showing the distribution of hemato-oncology trials by phase. The chart indicates Phase I at 13%, Phase II at 58%, Phase III at 10%, and Phase IV at 19%.

Robust Experience in Implementing Novel Drugs like:

Bispecific T-cell Engagers

Antibody-Drug Conjugates

Monoclonal, Bispecific and Trispecific Antibodies

Proteasome Inhibitors

Immunomodulatory Drugs

Stay Informed, Stay Ahead:
Insights Tailored for You

Multiple Myeloma: Opportunities and Challenges in the Changing Treatment Landscape
Webinar
Multiple Myeloma: Opportunities and Challenges in the Changing Treatment Landscape

Expert insights into the latest advancements, evolving treatment strategies, and the future of care for patients

Watch Now
A 3D-rendered medical illustration of a microscopic view of blood, showing large, irregular-shaped blue cells (possibly cancer or immune cells) among numerous red blood cells.
Brochure
Hematology-Oncology Research

Supporting Hemato-Oncology Trials Through Our Multi-layered Approach

Read More